Julie Fleshman, President and CEO of Pancreatic Cancer Action Network (PanCAN), shared a post on LinkedIn:
“I was once again on Capitol Hill today meeting with bipartisan Congressional leaders to emphasize the urgent need for sustained federal investment in pancreatic cancer research and patient care.
I was thrilled to be joined by Dr. Mustafa Raoof of City of Hope, Dr. Michael VanSaun of the University of Kansas Cancer Center, Dr. Mike Pishvaian of Johns Hopkins, and Dr. Anna Berkenblit, PanCAN Chief Scientific and Medical Officer. We spoke about the critical need to strengthen funding for the NCI and the Pancreatic Cancer Research Program at the DoD at an exciting and breakthrough moment for pancreatic cancer research.
The momentum in pancreatic cancer research is real. Emerging RAS inhibitors are opening promising new possibilities for patients, but advancing these discoveries into more effective treatments and improved outcomes will require sustained commitment and urgency. After 26 years at PanCAN, I know for certain that the partnership between researchers, donors, advocates and policymakers have the opportunity, and responsibility, to accelerate progress for every patient and family affected by pancreatic cancer”
Other articles featuring Julie Fleshman on OncoDaily.